Pelacarsen
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease, ASCVD
Conditions
Atherosclerotic Cardiovascular Disease, ASCVD
Trial Timeline
— → —
NCT ID
NCT07000695About Pelacarsen
Pelacarsen is a pre-clinical stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease, ASCVD. The current trial status is active. This product is registered under clinical trial identifier NCT07000695. Target conditions include Atherosclerotic Cardiovascular Disease, ASCVD.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07000695 | Pre-clinical | Active |
| NCT05900141 | Phase 3 | Active |
| NCT05026996 | Phase 1 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease, ASCVD